Press Release
InnoCare Releases 2022 mid-Year Results and Business Highlights
22 Aug, 2022
170
3931
InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma in China
12 Aug, 2022
103
3923
InnoCare to Host 2022 First Half Year Earnings Call on Aug. 22, 2022
09 Aug, 2022
100
3921
InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China
02 Aug, 2022
101
3918
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City’s Early Access Program
22 Jul, 2022
78
3913
InnoCare Announces Approval of Clinical Trial of Novel Targeted Protein Degrader ICP-490 in China
06 Jul, 2022
108
3902
Approval of Commercial Production in InnoCare's Guangzhou Facility
04 Jul, 2022
74
3900
InnoCare Announces First Patient Dosed in Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China
22 Jun, 2022
106
3854
Tafasitamab in Combination with Lenalidomide Recommended by the Chinese Society of Clinical Oncology Lymphoma Diagnosis and Treatment Guidelines for Relapsed/Refractory Diffuse Large B-cell Lymphoma
09 Jun, 2022
83
3786
Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2022 ASCO Annual Meeting
07 Jun, 2022
102
3774